Detection of a Novel Biomarker to Monitor Antiplatelet Therapy

尽管血小板对抗血小板药物的敏感性存在广泛的个体差异，但抗血小板治疗目前还没有通过实验室检测进行监测。在这项研究中，为了确定抗血小板药物作用的生物标志物，我们对接受抗血小板治疗的患者的血液样本进行了全面的研究和候选方法。综合研究和候选方法都表明，血浆糖钙素水平与血小板对阿司匹林的反应有关，糖钙素是血小板受体糖蛋白Ib α的细胞外结构域片段。本研究还开发了一种简便的糖钙素定量分析方案。

Although there are wide inter-individual variations in platelet sensitivity to antiplatelet drugs, antiplatelet therapy is currently not monitored with laboratory tests. In this study, to identify biomarker(s) of the effects of antiplatelet drugs, we performed comprehensive studies and candidate approaches on blood samples from patients receiving antiplatelet therapy. Both the comprehensive studies and candidate approaches showed that plasma levels of glycocalicin, known as fragments of extracellulardomain of a platelet receptor glycoprotein Ib alpha, were associated with platelet response to aspirin. This study also developed a facile protocol for quantitative analysis of glycocalicin.